Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke
Completed
Phase 1 Results N/AView Trial Locations
Recruitment
- Enrollment: 16
- Gender: Both
- Minimum Age: 50 Years
- Accepts Healthy Volunteers: No
- 5 locations, 5 countries
Principal Investigator
- Email contact via H. Lundbeck A/S
LundbeckClinicalTrials@lundbeck.com